Brief: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation For DYNE-251 In Duchenne Muscular Dystrophy
24/04/2025 13:09
April 24 (Reuters) - Dyne Therapeutics Inc DYN.O: DYNE THERAPEUTICS RECEIVES EUROPEAN MEDICINES AGENCY (EMA) ORPHAN DRUG DESIGNATION FOR DYNE-251 IN DUCHENNE MUSCULAR DYSTROPHY Source text: ID:nGNX96xf32 Further company coverage: DYN.O ((Reuters.Briefs@thomsonreuters.com;))